Lipocine (NASDAQ:LPCN) Upgraded at Wall Street Zen

Lipocine (NASDAQ:LPCN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Other research analysts have also issued reports about the company. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. Weiss Ratings downgraded Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $15.00.

Lipocine Stock Performance

LPCN opened at $2.23 on Friday. The firm’s fifty day moving average is $2.31 and its two-hundred day moving average is $5.33. The firm has a market cap of $18.38 million, a PE ratio of -1.19 and a beta of 0.44. Lipocine has a twelve month low of $1.81 and a twelve month high of $12.37.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%.The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.16 million. Equities analysts forecast that Lipocine will post -1.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Lipocine

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Squadron Capital Management LLC bought a new stake in Lipocine in the 4th quarter valued at $4,256,000. Eversept Partners LP acquired a new position in Lipocine in the 1st quarter worth $2,357,000. Diadema Partners LP bought a new position in Lipocine during the 4th quarter worth about $2,095,000. AIGH Capital Management LLC bought a new position in Lipocine during the 1st quarter worth about $1,598,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Lipocine in the 4th quarter valued at about $1,602,000. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.